vs
德康医疗（DXCM）与Globe Life（GL）财务数据对比。点击上方公司名可切换其他公司
Globe Life的季度营收约是德康医疗的1.2倍（$1.6B vs $1.3B），德康医疗净利率更高（21.2% vs 17.3%，领先3.9%），德康医疗同比增速更快（21.6% vs 5.3%），过去两年德康医疗的营收复合增速更高（12.0% vs 4.1%）
德康医疗是美国跨国医疗保健企业，专注于研发、生产及销售糖尿病管理领域的连续血糖监测（CGM）系列系统。其全球总部及研发中心位于美国加利福尼亚州圣地亚哥，生产基地分布于美国亚利桑那州梅萨、马来西亚峇都交湾及爱尔兰戈尔韦郡阿斯里。
Globe Life Inc.（股票代码：GL）是总部位于美国得克萨斯州麦金尼的金融服务控股公司，在纽约证券交易所上市，通过旗下全资子公司开展业务，主营人寿保险、年金产品及补充健康保险产品。
DXCM vs GL — 直观对比
营收规模更大
GL
是对方的1.2倍
$1.3B
营收增速更快
DXCM
高出16.2%
5.3%
净利率更高
DXCM
高出3.9%
17.3%
两年增速更快
DXCM
近两年复合增速
4.1%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.3B | $1.6B |
| 净利润 | $267.3M | $270.5M |
| 毛利率 | 62.9% | — |
| 营业利润率 | 25.6% | — |
| 净利率 | 21.2% | 17.3% |
| 营收同比 | 21.6% | 5.3% |
| 净利润同比 | 153.6% | 6.3% |
| 每股收益（稀释后） | $0.67 | $3.39 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DXCMGL
| Q1 26 | $1.3B | $1.6B | ||
| Q4 25 | $1.3B | $1.5B | ||
| Q3 25 | $1.2B | $1.5B | ||
| Q2 25 | $1.2B | $1.5B | ||
| Q1 25 | $1.0B | $1.5B | ||
| Q4 24 | $1.1B | $1.5B | ||
| Q3 24 | $994.2M | $1.5B | ||
| Q2 24 | $1.0B | $1.4B |
净利润DXCMGL
| Q1 26 | $267.3M | $270.5M | ||
| Q4 25 | $267.3M | $266.1M | ||
| Q3 25 | $283.8M | $387.8M | ||
| Q2 25 | $179.8M | $252.7M | ||
| Q1 25 | $105.4M | $254.6M | ||
| Q4 24 | $151.7M | $255.2M | ||
| Q3 24 | $134.6M | $303.0M | ||
| Q2 24 | $143.5M | $258.4M |
毛利率DXCMGL
| Q1 26 | 62.9% | — | ||
| Q4 25 | 62.9% | — | ||
| Q3 25 | 60.5% | — | ||
| Q2 25 | 59.5% | — | ||
| Q1 25 | 56.9% | — | ||
| Q4 24 | 58.9% | — | ||
| Q3 24 | 59.7% | 26.1% | ||
| Q2 24 | 62.4% | 23.3% |
营业利润率DXCMGL
| Q1 26 | 25.6% | — | ||
| Q4 25 | 25.6% | 21.7% | ||
| Q3 25 | 20.1% | 31.5% | ||
| Q2 25 | 18.4% | 21.2% | ||
| Q1 25 | 12.9% | 21.4% | ||
| Q4 24 | 17.0% | 21.3% | ||
| Q3 24 | 15.3% | 26.3% | ||
| Q2 24 | 15.7% | 23.5% |
净利率DXCMGL
| Q1 26 | 21.2% | 17.3% | ||
| Q4 25 | 21.2% | 17.5% | ||
| Q3 25 | 23.5% | 25.6% | ||
| Q2 25 | 15.5% | 17.1% | ||
| Q1 25 | 10.2% | 17.2% | ||
| Q4 24 | 13.6% | 17.4% | ||
| Q3 24 | 13.5% | 20.8% | ||
| Q2 24 | 14.3% | 17.9% |
每股收益（稀释后）DXCMGL
| Q1 26 | $0.67 | $3.39 | ||
| Q4 25 | $0.67 | $3.28 | ||
| Q3 25 | $0.70 | $4.73 | ||
| Q2 25 | $0.45 | $3.05 | ||
| Q1 25 | $0.27 | $3.01 | ||
| Q4 24 | $0.37 | $3.00 | ||
| Q3 24 | $0.34 | $3.44 | ||
| Q2 24 | $0.35 | $2.83 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $917.7M | $183.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.7B | $6.1B |
| 总资产 | $6.3B | — |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资DXCMGL
| Q1 26 | $917.7M | $183.8M | ||
| Q4 25 | $917.7M | $314.7M | ||
| Q3 25 | $1.8B | $62.8M | ||
| Q2 25 | $1.2B | $116.7M | ||
| Q1 25 | $904.9M | $134.1M | ||
| Q4 24 | $606.1M | $85.0M | ||
| Q3 24 | $621.2M | $100.5M | ||
| Q2 24 | $939.2M | $100.6M |
股东权益DXCMGL
| Q1 26 | $2.7B | $6.1B | ||
| Q4 25 | $2.7B | $6.0B | ||
| Q3 25 | $2.7B | $5.7B | ||
| Q2 25 | $2.6B | $5.4B | ||
| Q1 25 | $2.3B | $5.4B | ||
| Q4 24 | $2.1B | $5.3B | ||
| Q3 24 | $2.0B | $4.6B | ||
| Q2 24 | $2.4B | $5.2B |
总资产DXCMGL
| Q1 26 | $6.3B | — | ||
| Q4 25 | $6.3B | $30.8B | ||
| Q3 25 | $7.5B | $30.5B | ||
| Q2 25 | $7.3B | $29.8B | ||
| Q1 25 | $6.8B | $29.7B | ||
| Q4 24 | $6.5B | $29.1B | ||
| Q3 24 | $6.4B | $29.6B | ||
| Q2 24 | $6.8B | $28.3B |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DXCM
暂无分部数据
GL
| Life premium | $853.2M | 55% |
| Health premium | $416.9M | 27% |
| Other | $289.5M | 19% |
